Immunotherapy in oral cancer: Review | Balkan Journal of Dental Medicine

Papaioannou Despoina^a, Petsali Spyridoula^a, Ndreou Alida^a, Akritidou Fani^b, Zisis Vasileios^a, Kavvadas Dimitrios^b, Poulopoulos Athanasios^a, Karachrysafi Sofia^b, Andreadis Dimitrios^a

^aAristotle University of Thessaloniki, Faculty of Health Sciences, School of Dentistry, Department of Oral Medicine/Pathology, Thessaloniki, Greece
^bAristotle University of Thessaloniki, Faculty of Health Sciences, Department of Medicine, Laboratory of Histology-Embryology, Thessaloniki, Greece

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most prevalent malignant entity with a significant fatality rate. The International Agency for Research on Cancer reported in 2018 that there are approximately 350,000 newly diagnosed instances of oral cancer per year, amounting to a cumulative incidence of 4.0 per 100,000 people. The aim of this review was to investigate the biomarkers associated with immunotherapy in head and neck cancer, and in particular oral cancer, as well as their respective immunotherapeutic agents. An extensive review of the literature was carried through. Relevant articles were searched in Medline Pubmed, Web of Science and Google scholar. The inclusion criterion was that the article should be written in English, whereas the exclusion criterion was the opposite. The current standard of care (SOC) for disease that recurs locally and/or metastatic disease was, until recently, platinum-based chemotherapy plus cetuximab. A potential treatment option is the monoclonal antibody cetuximab, which extends median progression-free survival (PFS) as it targets the epidermal growth factor (EGFR). Last decade, research has shown that there are two mechanisms of tumor’s microenvironment (the immune escape and the T-cell exhaustion) which are related to total survival from cancer. Consequently, scientists focused on immunotherapy, a new therapeutic approach that activates a patient’s immune system to fight tumor cells. Immune checkpoint inhibitors (ICIs) are a category of immunotherapies that are extremely effective at reactivating the immune system’s defence against cancer. Oral cancer immunotherapy could target two significant immune checkpoints, cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed death-1 (PD-1).

Keywords: immunotherapy; oral cancer; CTLA-4; PD-1

Reference

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers, 2020;6:92

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer, 2019;7:184

Chen SH, Hsiao SY, Chang KY, Chang JY. New Insights Into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis. Int J Mol Sci, 2021;22:1-21

Deng WW, Mao L, Yu GT, Bu LL, Ma SR, Liu B, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology, 2016;5:e1239005

Elbehi AM, Anu RI, Ekine-Afolabi B, Cash E. Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncol, 2020;109:109:104977

Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol, 2015;33:2092-2099

Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol, 2018;52:228-240

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 2015;27:450

Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity, 2004;21:503-513

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol, 2019;16:563-580

Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab, 2020;34:101370

Velcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. Am Soc Clin Oncol Educ Book, 2016;35:298-308

Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother, 2016;12:2219-2231

Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev, 2017;276:80-96

Sato F, Ono T, Kawahara A, Kawaguchi T, Tanaka H, Shimamatsu K, et al. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol, 2019;72:542-549

Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol, 2018;52:39-52

Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol, 2017;18:1104-1115

Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol, 2019;99

Zaremba A, Eggermont AMM, Robert C, et al. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer, 2021;155:268-280

Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. Int J Mol Sci, 2019;20:5399

Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev, 2017;114:33-42

Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, et al. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol, 2018;19:1415-1426

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med, 2014;12:36

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, et al. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol, 2017;28:2526-2532

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med, 2016;375:1856-1867

Ferris RL, Licitra L, Fayette J, Guigay J, Colevas AD, MD, Lisa Licitra L, et al. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res, 2019;25:5221-5230

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinumbased chemotherapy. Eur J Cancer, 2019;107:142-152

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942-950

Wang BC, Li PC, Fan JQ, Lin GH, Liu Q. Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis. Medicine, 2020;99:E21273

Bourhis J, Stein A, Paul de Boer J, Van Den Eynde M, Gold KA, Stintzing S, et al. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treat Rev, 2021;97:102172

Merlano MC, Merlotti AM, Licitra L, Denaro N, Fea E, Galizia D, et al. Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. Clin Transl Radiat Oncol, 2018;12:47-52

Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grun J, Illmer T, et al. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/ tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer, 2020;8:e001378

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. Pembrolizumab for Platinum-and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol, 2017;35:1542-1549

Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, et al. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer, 2020;138:202-211

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer, 2018;119:153-159

Theodoraki MN, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, et al. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology, 2019;8:1593805

McBride S, Sherman E, Jillian Tsai C, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol., 2021;39:30-37

Brennan S, Baird AM, O’Regan E, Sheils O. The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma. Front Mol Biosci, 2021;8:677900

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol, 2018;19:1480-1492

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J ClinOncol, 2022;40:127-137

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/ Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol, 2019;5:195

Zuur CL, Elbers JBW, Vos JL, van der Leun A, Qiao X, Karakullukcu B, et al. Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637). J Clin Oncol, 2019;37:2575-2575

Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol, 2018;29:2247-2253

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel), 2021;13:2882

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebocontrolled, multicentre, phase 3 trial. Lancet Oncol, 2021;22:450-462

Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol, 2023;34:101-110

Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev, 2016;31:61-71

Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics, 2017;7:1543-1588

Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ. Regulation of Interleukin-8 Expression in Human Melanoma Cells by the Organ Environment. Cancer Res, 1995;55:2470-2475

Mehra R, Cohen RB, Burtness BA. The Role of Cetuximab for the Treatment of Squamous Cell Carcinoma of the Head and Neck. Clin Adv Hematol Oncol, 2008;6:742-750

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, et al. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res, 2019;25:3220-3228

Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, et al. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer, 2020;141:21-29

Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2015;16:375-384

D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med (Baltim), 2011;53:S5-S11

Julian R, Savani M, Bauman JE. Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. Cancers (Basel), 2021;13:5889

Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, et al. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. Cancer Res Treat, 2016;48:527-536

Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res, 2013;73:128-138

Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, et al. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer, 2019;7:252

Robert C, Schachter J, Long G V, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med, 2015;372:2521-2532

Dua D, Kelly C, Kovarik J, Iqbal MS. The role of combining immunotherapy with primary (Chemo) radiotherapy in curative treatment settings of the head and neck cancer. Asia Pac J Clin Oncol, 2022;18:e3-e10

Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci, 2020;12:16

Plavc G, Strojan P. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials. Radiol Oncol, 2020;54:377-393

Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res, 2020;30:507-519

Segal NH, Ou SHI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. Eur J Cancer, 2019;109:154-161

Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol, 2015;33:3293-3304

Von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE. Immunotherapy Use in Patients With Lung Cancer and Comorbidities. Cancer J, 2020;26:525-536

Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and metaanalysis. BMC Med. 2015;13:211

Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer, 2019;7:306

Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer, 2017;25:1713-1739

Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507

Balkan Journal of Dental Medicine, 2023, vol. 27, br. 3, str. 129-139

Papaioannou Despoinaa, Petsali Spyridoulaa, Ndreou Alidaa, Akritidou Fanib, Zisis Vasileiosa, Kavvadas Dimitriosb, Poulopoulos Athanasiosa, Karachrysafi Sofiab, Andreadis Dimitriosa

Abstract

Reference

Papaioannou Despoina^a, Petsali Spyridoula^a, Ndreou Alida^a, Akritidou Fani^b, Zisis Vasileios^a, Kavvadas Dimitrios^b, Poulopoulos Athanasios^a, Karachrysafi Sofia^b, Andreadis Dimitrios^a